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 69 
We identified bi-allelic mutations in NANS, the gene coding for N-acetyl-neuraminic 70 
acid (NeuNAc; sialic acid) synthase, in nine individuals with infantile-onset severe 71 
developmental delay and skeletal dysplasia. Patient body fluids showed an elevation of 72 
N-acetyl-mannosamine, and patient-derived fibroblasts had reduced NANS activity and 73 
were unable to incorporate sialic acid precursors into sialylated glycoproteins. 74 
Knockdown of nansa in zebrafish embryos resulted in abnormal skeletal development 75 
and exogenously added sialic acid partially rescued the skeletal phenotype. Thus, 76 
NANS-mediated synthesis of sialic acid is required for early brain development and 77 
skeletal growth. Normal sialylation of plasma proteins was observed in spite of NANS 78 
deficiency. Exploration of endogenous synthesis, nutritional absorption, and rescue 79 
pathways of sialic acid in different tissues and developmental phases is warranted to 80 
design therapeutic strategies for NANS deficiency and to shed light on sialic acid 81 
metabolism and its implications for human nutrition.  82 
 83 
Intellectual developmental disorders (IDDs) affect 2-2.5% of children and adults worldwide1. The 84 
developmental origin is reflected in its definition as “substantial impairments of intellectual 85 
function and social or adaptive functioning present from early childhood”2. Recent advances 86 
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have shown that in many cases, the etiology is genetic, most frequently due to de novo 87 
mutations3,4. Along with better understanding of the surrounding condition and prognosis, 88 
insights into the molecular basis of neurocognitive impairment allows for the development and 89 
application of targeted therapeutic strategies5. Although less frequent than IDD, genetic disorders 90 
affecting skeletal development and growth (commonly called the “skeletal dysplasias”) are a 91 
group of over 500 distinct disorders6. Studying their molecular basis has provided precious 92 
insights into the many factors necessary for skeletal development, ranging from minerals and 93 
structural molecules to enzymes, to signaling molecules and transcription factors6,7.  We report 94 
here a genetic disorder presenting with a combination of severe IDD with skeletal dysplasia and 95 
short stature. Our data show that its pathogenic basis is an inborn error of metabolism that 96 
affects the endogenous synthesis of N-acetyl neuraminic acid (NeuNAc; sialic acid). Exploration 97 
of the biochemical and molecular features of this disorder provides new information on the role 98 
of sialic acid in the development of brain and bone.  99 
 100 
RESULTS 101 
Clinical and radiographic phenotype of NANS deficiency 102 
The clinical patient reports are presented in extenso in the Supplementary Material. Nine patients 103 
from six families were studied; patients 1, 2, and 5 have been previously described8,9. The main 104 
clinical features are as follows: prenatal history was unremarkable in all patients except for one 105 
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(pt. 8), in whom prenatal hydrocephalus was diagnosed. No specific signs and symptoms were 106 
present at birth except for disproportionately short limbs that were observed in three patients 107 
(pts. 3, 8 and 9). In the first months of life, all patients showed muscle hypotonia, and the 108 
achievement of early developmental milestones such as sitting and walking was delayed. 109 
Subsequently, global developmental delay, including cognitive impairment, was the major 110 
medical concern. All adult patients showed moderate to severe IDD; only one patient acquired 111 
speech and none was living independently. Seizures were a prominent and early feature in one 112 
patient but were infrequent in some and absent in others. Social competences were relatively 113 
preserved. Body measurements at birth were normal or slightly reduced, but growth velocity 114 
decreased during the first or the second year of life, and short stature with shortening of both the 115 
trunk and the limbs was present in all adult patients. The facial features showed a prominent 116 
forehead, mild synophrys, a sunken nasal bridge, a prominent bulbous nasal tip, and full lips 117 
(Fig. 1). No endocrine anomalies were noticed and adult patients had gone through pubertal 118 
development. Neuro-imaging was available in six patients: patient 8 showed prenatal-onset 119 
hydrocephalus, while patient 9 showed perisylvian polymicrogyria, small basal ganglia and 120 
reduced white matter (Supplementary Figure 1); the other four patients showed moderate 121 
cerebral atrophy with nonspecific white matter changes. Distinct features that permitted to 122 
distinguish these individuals among the large group of persons with severe IDD were the facial 123 
dysmorphisms and the skeletal dysplasia with short stature, premature carpal ossification, 124 
platyspondyly, longitudinal metaphyseal striations, and small epiphyses (see Fig. 1 for details). 125 
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For more radiographic details, see also the previous clinical reports of patients 1 and 28 and 126 
patient 59 (pat. 1 in that reference). 127 
   128 
Identification of NANS mutations and functional analysis  129 
Exome sequencing was performed on genomic DNA from patients 1 to 4 (two couples of sibs). 130 
After the filtering pipeline (see Methods and Supplementary Table 1), only one gene, NANS, 131 
showed biallelic variants in all four patients (Table 1). A small insertion/deletion just 5’ of exon 4, 132 
c.449-10_449-5delGATTACinsATGG, was seen at heterozygosity in all four patients (reference 133 
transcript: ENST00000210444, NCBI Reference Sequence: NM_018946.3). In addition to this 134 
shared mutation, patients 1 and 2 (who were sisters) had a single nucleotide insertion predicted 135 
to result in a frameshift with early truncation (c.389_390insT, p.Lys131GlnfsTer8), while patients 136 
3 and 4 (who were brother and sister) had a canonical splice donor site mutation (c.448+1G>A). 137 
Computational haplotype reconstruction using exome data revealed a specific haplotype 138 
encompassing a region of 1.38 MB on chromosome 9 (from 9:100388119 (rs10817858) to 139 
9:101767385 (rs41305481)) in the four individuals carrying the intronic insertion/deletion, 140 
indicative of a common origin. Sanger sequencing was used to confirm the mutations and to 141 
verify segregation with disease in all families. To test for pathogenicity of these variants, NANS 142 
cDNA was retrotranscribed from fibroblasts or lymphoblastoid cell RNA from patients 1, 3, and 143 
4, as well as the parents of patients 3 and 4, incubated with or without cycloheximide, PCR-144 
amplified and analyzed by capillary electrophoresis (Supplementary figure 2). The c.449-10_449-145 
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5delGATTACinsATGG insertion/deletion (patients 1, 2, 3 and 4) resulted in very low levels of 146 
mRNA, with presence of wild-type mRNA as well as an isoform lacking both exons 3 and 4 (in-147 
frame); in presence of cycloheximide, this allele appeared to produce additional abnormally 148 
isoforms, that apparently were subject to NMD. The c.448+1G>A variant (patients 3 and 4) 149 
produced two splicing isoforms, one lacking both exons 3 and 4 (similar to the previous 150 
mutation) and expressed at levels comparable to the wild-type allele, and very low levels of an 151 
out-of-frame isoform lacking exon 3 and part of exon 4. The exonic insertion c.389_390insT 152 
(patients 1 and 2) triggered nonsense-mediated RNA decay (NMD), as shown by sequencing of 153 
RT-PCR clones obtained from cells with or without cycloheximide. Thus, all three mutations 154 
resulted either in unstable or nonfunctional NANS mRNA or in reduced levels of wild-type 155 
transcripts. We then screened patients 5, 6, 7, and 8 by selective PCR amplification of NANS 156 
exons from genomic DNA and direct bi-directional Sanger sequencing of the amplicons, and 157 
found bi-allelic mutations in all patients, including four missense mutations and one triplet 158 
insertion leading to the duplication of one amino acid (Table 1 and Fig. 2).  159 
 160 
Investigation of patient 9, the youngest patient in our series, followed a different course; he was 161 
enrolled into the TIDEX study which combines genomics and metabolomics screening10. 162 
Metabolomic screening had revealed an unusual metabolite, N-acetylated mannosamine 163 
(ManNAc), in plasma and urine of this child (see below). Among the variants identified by 164 
exome sequencing in this patient, two missense mutations in NANS stood out as ManNAc-165 
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phosphate is the substrate of the NANS enzyme and malfunction of this enzyme would have 166 
accounted for the ManNAc accumulation in body fluids. The NANS variants identified in patient 167 
9 were confirmed via Sanger sequencing and shown to segregate correctly in the family. Of note, 168 
the exome results of patients 1, 2, 3, 4 and 5 were examined for possible pathogenic mutations in 169 
the GNE gene (see below) and none was observed. After this stage, the data of patients 1-8 and 170 
those of patient 9 were combined for all subsequent studies.  171 
 172 
Mapping of mutations on the 3D protein model of NANS  173 
The NANS protein was modeled as a homo-dimer based on the Neisseria homolog, as well as on 174 
recent results supporting dimer formation for the human protein11. Of the predicted amino acid 175 
changes (Table 1), four mapped in or near the active site: p.Lys131Gln, p.Gly133Val, 176 
p.Tyr188His, and p.Pro189Leu. It is likely that any of these would affect the catalytic activity of 177 
the enzyme, either by changing the ability of the protein to bind substrate (p.Lys131 and 178 
p.Tyr188 are also predicted to make H-bonds with the substrates11, fig 2), by changing the pocket 179 
shape (p.Gly133Val) or by affecting functional residues in the active site (p.Pro189 is located 180 
right next to p.Tyr188).  Mutations p.His29Asn and p.Arg237Cys are localized at the dimer 181 
interface and likely affect the folding,  protein stability and/or dimer formation.  While close to 182 
the dimer interface, the p.Ile327 that is duplicated is not involved in protein contacts in our 183 
model and it could be affecting folding instead. Finally, p.Arg151His is located on the surface of 184 
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the protein and away from the dimer interface and substrate-binding site, possibly interfering 185 
with folding or with a critical protein interaction.  186 
 187 
NANS mutations lead to accumulation of ManNAc in vivo 188 
Next generation metabolic screening (see Methods) was first applied to cerebro-spinal fluid 189 
(CSF) of patient 9 (Figure 3 and Supplementary Table 2), and then to plasma of patients 1-4 and 190 
9 (data not shown), leading to the identification of an unusual compound, N-acetyl mannosa-191 
mine, in all 5 patients. Quantitative NMR spectroscopy was then used to determine the 192 
concentration of N-acetyl mannosamine in available patients’ urine samples. In patients 1, 2, 3, 4 193 
and 8 (all adults at the time of study), the urinary concentration of ManNAc ranged from 41 to 194 
98 µmol/mmol creatinine (reference values, <10), whereas in patient 9 (age 3 years) excretion was 195 
highest (295 µmol/mmol creatinine). NMR spectroscopy was applied to homogenates of cultured 196 
fibroblasts to explore the intracellular sialic acid synthesis pathway. In fibroblasts from two unre-197 
lated patients (patients 3 and 9), this showed increased intracellular levels of N-acetylmannosa-198 
mine-6-phosphate rather than of free ManNAc. NANS can act as a N-acetylneuraminic acid 199 
phosphate synthase (MIM 605202; EC 2.5.1.57).  This may account for the accumulation of N-200 
acetylmannosamine in body fluids and N-acetylmannosamine-6-phosphate within the cell. The 201 
free NeuNAc concentration in fibroblasts was normal (supplementary table ST2). Finally, we 202 
evaluated whether the deficient activity of NANS would lead to systemic deficiency of sialic acid. 203 
The concentration of free NeuNAc was evaluated in urine of 5 patients from 4 families (relative 204 
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to creatinine excretion) as well as in the CSF of patient 9. In all patients, normal values were 205 
found (Supplementary Table 3) suggesting that there was no systemic depletion of free 206 
neuraminic acid. Analysis of plasma transferrin- and apolipoprotein C-III isoforms, to evaluate 207 
the biosynthesis of N- and O-glycans respectively, has been done repeatedly on several of the 208 
patients in the clinical setting as well and given normal results (Supplementary Table 4), further 209 
contributing to the notion that peripheral sialylation was not significantly affected despite NANS 210 
deficiency.  211 
 212 
NANS mutations impair enzyme activity  213 
In two preliminary experiments, we explored the sialylation of proteins and lipids at the cell 214 
surface of patient and control fibroblasts using FITC-labelled Sambucus nigra lectin (that 215 
specifically binds to terminal galactose-bound sialic acid residues) and FACS analysis, and we 216 
determined the cellular content of CMP-NeuNAc and total NeuNAc before and after addition of 217 
10 mM ManNAc12 . No differences between patient and control fibroblasts were seen, possibly 218 
because the concentration of ManNAc used was significantly higher than what is found 219 
physiologically. We then developed a method to measure NANS enzyme activity in cell lysates by 220 
incubation with ManNAc-6-P and phosphoenolpyruvate (PEP) and quantification of newly 221 
formed NeuNAc by mass spectrometry (Fig. 3, panel D). In comparison with five healthy 222 
controls (613+/-150 nmol NeuNAc/mg protein, mean +/-SD), the three available patient 223 
fibroblast lines showed reduced production of NeuNAc (163+/-111 nmol NeuNAc/mg protein, 224 
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mean +/-SD) at 24h incubation. Fibroblasts from the heterozygous father of patient 3 and 4 225 
showed intermediate NANS activity (403 nmol NeuNAc/mg protein). Although the residual 226 
activity in this assay was high, these results were in agreement with an autosomal recessive defect 227 
in NANS.  228 
 229 
Incorporation of ManNAc into sialoglycoproteins is impaired  230 
We then used metabolic labeling of sialic acids using propargyloxycarbonyl(Poc)-derivatized 231 
analogs of ManNAc and NeuNAc (ManNPoc and NeuNPoc, respectively) 13, a recently developed 232 
technique that had been useful to confirm deficient sialic acid incorporation in cells deficient for 233 
the Golgi transporter of CMP-sialic acid14. NeuNPoc, which enters the metabolic pathway 234 
downstream of the enzymatic step catalyzed by NANS, was incorporated efficiently into 235 
glycoproteins in all cell lines analyzed, while ManNPoc, which enters the pathway upstream (Fig. 236 
4), was incorporated in fibroblasts from a control and from a NANS heterozygote, but not in 237 
those of patients 3, 8, and 9 (Fig. 3). These data confirmed the functional impairment of NANS 238 
activity on the metabolic pathway of sialic acid biosynthesis and protein sialylation. NANS 239 
deficiency should therefore be included among the list of CDGs (congenital disorders of 240 
glycosylation). Importantly, these data suggest that exogenous NeuNAc might be used to bypass 241 
the enzymatic block (see Discussion, below). 242 
 243 
nansa knockdown perturbs zebrafish skeletal development  244 
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There are two zebrafish orthologs for the human NANS gene, the nansa and nansb genes (see 245 
Methods for detail). Nansa is expressed during early embryonic development including stages of 246 
50% epiboly in the axis, 1-13 somites at the notochord and polster, and 14-19 somites at the 247 
hatching gland. Thereafter, nansa is strongly expressed in the head, immature eye, myotome, 248 
optic tectum and pharyngeal arch skeleton 15 . The expression pattern of nansb is unknown. We 249 
designed splicing morpholinos to knockdown both nansa and nansb genes 16 (see Methods). 250 
Microinjection of nansa morpholino into the newly fertilized zebrafish eggs resulted in embryos 251 
with small head, pericardial edema, and developmental anomalies of the skeleton, revealed by 252 
alcian blue staining, at 6dpf (Fig. 5 A, B). Interestingly, nansa morphants showed a complex 253 
phenotype in the area of the head, including hypoplastic or absent of Meckel’s cartilage, lack of 254 
basihyal, shortened and abnormal ethmoid plate, trabecula, parachordal, palatoquadrate, and 255 
absence of the ceratobranchial structures (Fig. 5 B) 17 . Nansb knockdown morphants did not 256 
show an overt phenotype even at higher concentrations of morpholinos (data not shown). 257 
 258 
Partial rescue of skeletal development by exogenous NeuNAc 259 
Given the position of nansa (and NANS) in the synthetic pathway of NeuNAc (see above), we 260 
tested whether the addition of sialic acid in zebrafish embryo water would rescue the head and 261 
skeleton developmental phenotypes of nansa zebrafish morphants.  Sialic acid at 200 µM resulted 262 
in partial rescue of the skeletal phenotype as measured by the reappearance and development of 263 
Meckel’s cartilage structure; this was correctly formed in 9% of embryos in basic nansa 264 
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knockdown conditions, but in 61% of embryos when sialic acid was added to the water (Fig. 5 C, 265 
D). Interestingly, the rescue effect of sialic acid was time-dependent; rescue was observed when 266 
sialic acid was added to the fish water right after morpholino injection, but not when it was 267 
added 24 hours post fertilization, suggesting that sialic acid plays a critical role in early 268 
embryonic development, potentially in cartilage and skeleton cell lineage specification or growth. 269 
 270 
 271 
DISCUSSION 272 
We present evidence that biallelic deleterious mutations in NANS are associated with a severe 273 
intellectual developmental disorder and skeletal dysplasia. First, we identified 10 different NANS 274 
variants in 9 patients from 6 unrelated families, segregating according to a recessive disease 275 
model. Second, the NANS mutations impaired the activity of the N-acetyl-neuraminic acid 276 
synthase enzyme as evidenced by reduced enzyme activity and by the specific block of N-acetyl 277 
mannosamine analogue incorporation in cultured cells. Third, dysfunction of NANS in vivo was 278 
confirmed by the accumulation of substrates of the missing enzyme: N-acetyl mannosamine in 279 
body fluids, and N-acetyl-mannosamine 6-phosphate in cultured cells. Finally, inactivation of the 280 
enzyme activity in zebrafish embryos resulted in a complex phenotype including abnormal 281 
development of skeletal structures. The conclusion that NANS mutations are the cause of the 282 
clinical phenotype is strengthened by the fact it was reached by two independent approaches. 283 
Patients 1 to 8 were ascertained because of their phenotype of intellectual disability and specific 284 
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skeletal dysplasia, and the genomic approach led to identification of NANS mutations and to 285 
their validation through RNA studies. Patient 9 was subjected to metabolomic screening first in 286 
order to elucidate the cause of severe IDD and dysmorphisms, leading to the identification of 287 
ManNAc in body fluids, and this biochemical phenotype allowed to prioritize the NANS 288 
mutations as the most likely pathogenic amongst the variants found subsequently on exome 289 
sequencing. Although most of our patients were ascertained retrospectively and the clinical 290 
assessment is heterogeneous, there are indications for different degrees of clinical severity. The 291 
study of additional patients is needed to determine the clinical spectrum of NANS deficiency and 292 
to establish possible genotype-phenotype correlations.  293 
 294 
Brain contains the highest concentration of total sialic acid among human organs18. Sialic acid is 295 
present on glycoproteins and glycolipids such as the gangliosides, that are particularly abundant 296 
in nervous tissue, and NANS is highly expressed in the human brain (Supplementary Figure 3). 297 
Genetic deficiency of either sialyltransferase ST3GAL3 (MIM#604402) or ST3GAL5 298 
(MIM#609056), two enzymes that utilize CMP-NeuNAc to add terminal sialic acid residues to 299 
the glycosidic antennae of glycoproteins and glycolipids, leads to infantile epilepsy and/or 300 
developmental arrest, suggesting that appropriately sialylated glycoproteins and/or glycolipids 301 
are necessary for higher brain functions19-22. Mutations in the CMP-NeuNAc transporter 302 
SLC35A1 (MIM#605634; see Fig. 4) result in developmental disability with ataxia and bleeding 303 
diathesis 23. The observation of IDD in NANS-deficient patients and the brain dysplasia observed 304 
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in two of them underlines the relationship between sialylation and neurologic functions and 305 
indicates that the requirements for sialic acid in the developing brain must be met at least 306 
partially by endogenous synthesis of sialic acid through the NANS pathway.  307 
 308 
The short stature and skeletal dysplasia in NANS-deficient individuals also tells us that NANS-309 
mediated sialic synthesis plays a pivotal role in skeletal development, specifically at the growth 310 
plate cartilage. The skeletal anomalies seen in the zebrafish knockdown model confirmed this 311 
notion. The avascular nature of cartilage may make it dependent on endogenous synthesis. 312 
Several of the key players in cartilage and bone growth and development, such as chondroitin 313 
sulfate proteoglycans24, bone sialoprotein25 and osteopontin26, are heavily sialylated and will be 314 
candidates for further studies.  315 
 316 
Tests detecting hyposialylated transferrin and apolipoprotein C-III yielded normal results in our 317 
NANS-deficient patients, and there was no clinical or laboratory evidence of hyposialylation of 318 
plasma proteins or clotting factors, suggesting that sialylation of plasma proteins is not 319 
significantly affected. How is sialylation achieved with impaired NANS activity? Several lines of 320 
explanation can be considered. First, the mutations in our patients may allow for some residual 321 
activity; none of our patients had a combination of two bona fide null alleles. Secondly, 322 
endogenous NeuNAc synthesis may be rate limiting in certain tissues and at certain times, where 323 
and when synthetic requirements are maximal (such as in the brain, in periods of rapid growth 324 
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before birth and in the first two years of life27-29, or in cartilage during infancy and childhood), 325 
but not in other tissues where synthetic requirements for sialic acid may be lower. Such a 326 
mechanism has been put forward to explain the muscle-restricted phenotype of GNE myopathy 327 
(MIM# 603824)30, a disorder caused by recessive mutations in the GNE gene coding for UDP-N-328 
acetylglucosamine 2-epimerase and ManNAc kinase activities in the sialic acid synthesis pathway 329 
(Fig. 4). Thirdly, some tissues may be able to rescue and recycle sialic acid derived from the 330 
lysosomal breakdown of sialylated macromolecules (see Fig. 4). A fourth possibility, not mutually 331 
exclusive with the others, is that nutrition-derived sialic acids may be entered into biosynthetic 332 
pathways, and that this may occur in some tissues, such as the liver, but not, or to a lesser extent, 333 
in brain or cartilage. The observation of normal levels of free sialic acid in the urine of our 334 
NANS-deficient patients also indicates that there is no systemic depletion of sialic acid. 335 
 336 
The role of nutrition-derived sialic acid raises the question of a possible treatment with oral sialic 337 
acid in NANS-deficient individuals, in analogy to other glycosylation and sialylation defects, 338 
such as CDG1B (MIM# 602579) and GNE myopathy31, that have been amenable to treatment by 339 
oral administration of specific sugars. Some of our data may indeed point in this direction. When 340 
added to patients’ cells in culture, the sialic acid analogue NeuNPoc (used because of its 341 
detectability), but not the upstream metabolite ManNPoc, was able to bypass the enzymatic block 342 
and be incorporated into macromolecules. In zebrafish embryos, exogenously added sialic acid 343 
was able to partially recue the developmental phenotype caused by NANS knockdown. Could 344 
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dietary supplementation with sialic acid be beneficial for NANS deficient patients? There is 345 
evidence that free sialic acid can be taken up and metabolized by cultured cells32; this could occur 346 
through pinocytosis and release to the cytoplasm by the lysosomal sialic acid exporter (SLC17A5; 347 
Fig. 4). In animal models, sialic acid injected in the peritoneum is incorporated into 348 
macromolecules33, and orally administered free sialic acid is found in plasma and subsequently in 349 
the liver and the brain29,33. N-glycolyl-neuraminic acid, a sialic acid analogue that is widespread in 350 
mammals and apes but absent in man because of an evolutionary mutation, is found in human 351 
tissues as the result of dietary uptake from meat products34,35. Altogether, there is evidence 352 
indicating that alimentary sialic acids can be taken up and incorporated into biosynthetic 353 
pathways in the human. The relative contributions of endogenously synthesized, nutritionally 354 
derived, and rescued sialic acid in different tissues and at different developmental stages in man 355 
remain to be investigated and may explain how the consequences of NANS deficiency are 356 
restricted to the developing brain and cartilage. Particularly, if the brain pathology in NANS 357 
deficiency occurs in the first months of life (and perhaps even prenatally), this might be an 358 
obstacle to efficient treatment. Extensive studies in cell culture and in vivo are needed before 359 
envisaging any treatment possibility for NANS-deficient individuals. Such studies would also 360 
have the potential of clarifying the role of nutritional sialic acid in the human (see below).       361 
 362 
Human milk contains a high concentration of free oligosaccharides, most of which are 363 
sialylated27,28,36, 37, as well as free sialic acid.  These oligosaccharides, that are notably absent from 364 
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cow’s milk and infant formulas, have been attributed numerous functions, including stimulating 365 
brain development and cognition in infants27,28,37,38. Since oral administration of sialic acid in 366 
humans is considered safe and well-tolerated, nutritional supplementation with sialic acid in 367 
infancy, gestation and advanced age has been proposed27-29,37. In view of the role and potential of 368 
sialic acid in nutrition, exploring the pathogenesis of brain dysfunction and skeletal dysplasia 369 
induced by NANS deficiency is worthwhile not only to elaborate therapeutic approaches for 370 
NANS-deficient individuals, but also to shed light on sialic acid metabolism with its implications 371 
for human nutrition.  372 
 373 
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LEGENDS TO FIGURES  571 
 572 
 573 
Fig. 1. Morphologic and skeletal features in NANS deficiency.  574 
A, B: patient 9 at age 6 months (A)  and  at age 3 years (B); C,D: patient 8 at age 28 years; E,F: 575 
patient 4 at age 24 years; G,H; patient 3 at age 28 years; I,J: patient 2 at age 38 years; K,L: patient 1 576 
at age 40 years. Only short limbs are apparent at age 6 months; facial dysmorphism with 577 
prominent forehead, saddle nose, full lips and coarsening of traits is apparent at age 3 years. All 578 
adult patients have short stature (height between 130 and 150 cm). All photographs obtained and 579 
published with consent. M, N, O: lateral spine films show coronal clefts at birth (M, patient 8), 580 
severe vertebral body dysplasia at age 3 (N, patient 9); in adulthood, the vertebral bodies have a 581 
normal shape (O, patient 2). At the knees, there are metaphyseal striations and small epiphyses 582 
(epi-metaphyseal dysplasia) at age 9 years (P, patient 8); in adulthood, epiphyses remain small 583 
but metaphyseal striations have disappeared (Q, patient 2). Advanced carpal ossification at age 584 
21 months (R, patient 9), and metaphyseal striations (distal radius) with epiphyseal dysplasia at 585 
age 9 years (S, patient 8). Short femoral necks and small, irregular capital femoral epiphyses (epi-586 
metaphyseal dysplasia) at age 3 years 7 months (T, patient 9); in the adult (U, patient 3) short 587 
femoral neck and small epiphyses but bone and cartilage structure appear normal. Compare the 588 
radiographic images of patients 1 and 2 and patient 5 as reported earlier8,9. 589 
 590 
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Fig. 2. 3D model of NANS protein and mapping of amino acid residues affected by mutations 591 
A : Model of the human NANS protein, showing one monomer in grey and one in blue. Mutated 592 
residues are color-coded based on the patient with each allele mapped on a separate monomer. 593 
Lys131 and Arg151 are shown on both monomers. B and C: Detailed view of the location of the 594 
mutations. PEP: phosphoenolpyruvate. 595 
 596 
Fig. 3. Evidence of impaired NANS activity ex vivo and in cell culture. A,B,C: 500 MHz 1D 1H-597 
NMR spectra of body fluids and model compounds: A. CSF of patient 9 containing N-598 
acetylmannosamine at 180 µmol/L (reference <5). Resonances of alpha and beta forms of N-599 
acetylmannosamine are shown in the inserts B. relevant part of the CSF spectrum (a), compared 600 
with the spectrum of ManNAc (b), GalNAc (c), and GlcNAc (d);  C. Spectra obtained from 601 
fibroblasts of a control (a), patient 8 (b) and model compound ManNAc-6-P. D: NANS enzyme 602 
activity in fibroblast lysates. E: Metabolic labeling of sialylated proteins. Fibroblasts from a 603 
control (ctr), the heterozygous father of patients 3 and 4 (father), and patients 4, 8 and 9 (see 604 
table 1) were incubated with peracetylated propargyloxycarbonyl analogs of ManNAc and 605 
NeuNAc - ManNPoc and NeuNPoc respectively (see Fig. 4 for their entry point in the sialic acid 606 
biosynthetic pathway). Cell proteins were detected by Western blotting using streptavidin-HRP 607 
(upper panels) or antibodies against GAPDH (lower panels) as internal control. In cells from the 608 
control and from the heterozygous father, both ManNPoc and NeuNPoc result in strong labeling 609 
of proteins. In patients’ cells, ManNPoc (that enters the synthetic pathways upstream of NANS) 610 
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is unable to label the proteins, while NeuNPoc (that enters downstream the NANS enzyme) is 611 
incorporated efficiently. This confirms a metabolic block between ManNAc and NeuNAc, 612 
consistent with impaired NANS activity.  613 
 614 
Fig. 4. Simplified scheme of N-acetyl neuraminic acid metabolism in the human.  Biosynthesis 615 
of NeuNAc is achieved largely in the cytoplasm, except for the CMAS (**) reaction that takes 616 
place in the nucleus (nuclear membrane and its possible transporters omitted here for 617 
simplicity). The synthesis of N-acetyl mannosamine is carried out in two steps by the 618 
bifunctional enzyme, GNE/ManNAc synthase (*). N-Acetyl-neuraminic acid synthase (NANS) is 619 
indicated in red. CMP-sialic acid is transferred by a specific transporter, SLC35A1, into the 620 
medial- and trans-Golgi where it is used as a substrate for the sialylation of proteins and lipids by 621 
various sialyltransferases. - When sialylated glycoproteins and lipids are degraded in the 622 
lysosome, the free sialic acid released by sialidases can diffuse out of the lysosome through the 623 
lysosomal sialic acid transporter (SLC17A5). Free NeuNAc (as well as the non-human sialic acid, 624 
NeuNGc) can be taken up by pinocytosis and released into the cytoplasm by the SLC17A5 625 
transporter. Free sialic acid can then re-enter the biosynthesis pathway (indicated as “salvage” in 626 
the scheme). The relative importance of biosynthesis and salvage in different cell types and 627 
tissues is largely unknown. The metabolic scheme also shows the entry points of the two 628 
synthetic analogs used in this study, ManPoc and NeuNPoc (see text), the first being upstream, 629 
the second downstream of the step catalyzed by NANS.  630 
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 631 
 632 
Fig. 5. Abnormal skeletal development in nansa morpholino knockdown zebrafish is partially 633 
rescued by exogenous sialic acid. A, B: nansa-e3i3 morphants (4ng/nl) demonstrate small head, 634 
pericardial edema and abnormal cartilage and skeleton development including hypoplastic or 635 
absent of Meckel’s cartilage (m) and lack of basihyal (bh), shortened and abnormal ethmoid plate 636 
(ep), trabecula (tr), parachordal (pch), palatoquadrate (pq) and ceratobranchial (cb) structures in 637 
dorsal and ventral view. Abbreviations used: lateral: m, Meckel’s cartilage; bh, basihyal; dorsal: 638 
ep, ethmoid plate; tr, trabecula; pch, parachordal; ventral: m, Meckel’s cartilage; ch, ceratohyal 639 
cartilage; cb, ceratobranchial; pq, palatoquadrate. C, D: 200 µM sialic acid partially rescued the 640 
abnormal skeletal phenotype as measured by Meckel’s cartilage analysis. P1 - complete Meckel’s 641 
cartilage. P2 - incomplete Meckel’s cartilage, P3 - absent of Meckel’s cartilage. The graph in D 642 
shows the proportion of fish showing a Meckel’s cartilage phenotype of P1, P2 or P3 with or 643 
without exogenously added sialic acid. For each experimental condition, approx. 10-12 embryos 644 
were analyzed (actual numbers shown in the figure); experiments were done in triplicate. Bars 645 
represents SD between the triplicates. In the nansa–e313 morpholino treated animals, the 646 
difference between with or without 200 µM sialic acid is statistically significant: (*) p=0.05 for P1 647 
embryos, and (**) p.=0.01 for P3 embryos (two-tailed T-test).    648 
 649 
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Table 1. Overview of NANS mutations observed in the nine patients. 
 
*Transcript: ENST00000210444 (CCDS6733) NCBI Reference Sequence: NM_018946.3; ** ExAC database: 
http://exac.broadinstitute.org/, accessed November 2015; Wellderly database: Scripps Wellderly Genome Resource, The 
Scripps Wellderly Study, La Jolla, CA (URL: stsi-ftp.sdsc.edu), accessed January 2016. – *** 
http://genetics.bwh.harvard.edu/pph2/- **** http://provean.jcvi.org/index.php 
genomic DNA 
position (chr. 9) 
cDNA 
position* 
exo
n protein 
presence in 
databases** PolyPhen***	
Provean
****	
observed
in 
patient(s
) 
100819175 c.85C>A 1 p.His29Asn no 
probably
damaging 
deleterio
us Pat. 8 
100839236 
c.389_390insT 
 3 p.Lys131GlnfsTer8  
Wellderly: 
0.0008 n.a.	 n.a.	
Pat. 1 and 
2  
100839249 c.398G>T 3 p.Gly133Val no 
probably 
damaging 
deleterio
us 
Pat. 6 and 
7 
100839300 c.448+1G>A 3 aberrant splicing of exons 3 and 
4 as seen in mRNA studies 
ExAC=0.00002
633 
n.a. n.a. Pat. 3 and 
4 
100840462 
  c.449-10_449-
5delGATTACinsATG
G§ 
4 
aberrant splicing of exons 3 and 
4 as seen in mRNA studies 
ExAC = 
0.00004947 n.a. n.a. 
Pat. 1 and
2 
Pat. 3 and 
4 
100840478 c.452G>A 4 p.Arg151His Wellderly: 0.0008 
probably 
damaging neutral 
Pat. 5
(homozyg
ous) 
100840588 c.562T>C 4 p.Tyr188His no probably 
damaging 
deleterio
us 
Pat. 9 
100840592 c.566C>T 4 p.Pro189Leu no 
probably 
damaging 
deleterio
us Pat. 8 
100843203 c.709C>T  p.Arg237Cys no 
probably 
damaging 
deleterio
us Pat. 9 
100845238 c.981insATC 6 p.Ile327dup no 
probably 
damaging 
deleterio
us 
Pat. 6 and 
7 
650 
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METHODS  651 
 652 
Ethics - The studies were approved by the ethics boards of the following institutions: BC 653 
Children’s & Women’s Hospital, University of British Columbia (#12-00067), the Ethics Board of 654 
the Lausanne University Hospital. Research was performed according to the countries’ ethics 655 
code of conduct. Parents or guardians provided written informed consent for the biochemical 656 
and genetic analysis and the publication of photographs and clinical data. 657 
 658 
Identification of mutations in NANS – For patients 1 to 4, fragmented genomic DNA was 659 
purified with AMPure XP beads and its quality was assessed with an Agilent Bioanalyzer. 660 
Preparation of the exome enriched, barcoded sequencing libraries was performed using the 661 
SureSelect Human All Exon v4 kit (Agilent). The final libraries were quantified with a Qubit 662 
Fluorometer (Life Technologies) and the correct size distribution was validated on the Agilent 663 
Bioanalyzer. Libraries were then sequenced on a HiSeq 2000 machine (Illumina), generating 100 664 
bp paired-end reads. Raw reads were aligned onto the hg19 reference genome using the 665 
Novoalign software. Data cleanup and variant calling were performed according to GATK Best 666 
Practices recommendations39. Variant filtering was made with Annovar40 and with in-house perl 667 
and bash scripts, available upon request. For patient 9, who was genotyped in the Vancouver lab, 668 
similar procedures were used. To verify for the presence of a possible ancestral haplotype 669 
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carrying the NANS ins/del in patients 1 to 4, we extracted all SNP alleles that were present in the 670 
region surrounding NANS and that were listed in the dbSNP database. Local genotypes were 671 
then scored, and likely haplotypes were constructed. – In patients 5 to 8, all individual exons of 672 
NANS were amplified from genomic DNA (primers available upon request) and sequenced 673 
directly in both directions using the Sanger method.  For patient 9, exome sequencing was 674 
performed as part of the TIDEX gene discovery project using using the Agilent SureSelect kit 675 
(Agilent Technologies) and Illumina HiSeq 2000 (Illumina). The sequencing reads were aligned 676 
to the human reference genome version hg19 (coverage 35X) and rare variants were identified 677 
and assessed for their potential to disrupt protein function. In total, we identified 19 candidate 678 
genes affected by 2 rare heterozygous variants. Of these, NANS stood out as the most interesting 679 
functional candidate because of the pre-existing next-generation metabolomics data. Sanger 680 
sequencing in the patient and his parents confirmed the mutations and segregation with disease.  681 
 682 
Construction of a 3D protein model for NANS and mapping of the predicted mutations - A 683 
molecular model for the dimeric full-length human NANS protein was generated with I-684 
TASSER41, using as templates the Neisseria meningitidis homolog42 and the human AFPL 685 
domain43 structures. The model illustrations were generated with the PyMOL Molecular 686 
Graphics System, Version 1.7.4, Schrödinger, LLC. 687 
 688 
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mRNA studies - Lymphoblastoid cell lines were cultured in suspension under 5% CO2 in T25 689 
flasks with RPMI Medium 1640 + GlutaMAX-I (Gibco) containing 10% FBS (Gibco, ref. 10270-690 
106), 1% penicillin/streptomycin (Gibco), whereas fibroblasts were cultured in DMEM (1X) with 691 
1g/L D-glucose L-glutamine (Gibco), supplemented with 10% FBS and 1% 692 
penicillin/streptomycin. To test for nonsense-mediated mRNA decay (NMD), treatment with 693 
cycloheximide (Sigma-Aldrich) was performed in parallel with controls by incubating 10 million 694 
cells for 4 hours in the presence of medium supplemented with 28 μg/ml of this chemical, 695 
according to published protocols44. Total RNA was isolated from both cycloheximide-treated and 696 
untreated fibroblast and lymphoblast cultures by using the Direct-zol RNA MiniPrep kit (Zymo 697 
Research) according to the manufacturer’s instructions. cDNA was prepared following the 698 
retrotranscription of 500 ng RNA, by using the PrimerScript RT-PCR kit (Clontech) and random 699 
hexamers; 10 ng of the produced cDNA were then used as template for downstream experiments. 700 
A specific primer pair spanning the exon-exon junctions 1-2 and 5-6 (for sequences, see 701 
Supplementary Table 5) was designed to amplify the regions of the NANS cDNA containing all 702 
mutations studied. RT-PCRs were performed in triplicate in a final reaction volume of 20 μl 703 
containing 5X Green GoTaq reaction buffer (Promega), 100 µM dNTP mix, 200 nM of each 704 
primer, and 0.1 U of GoTaq G2 DNA Polymerase (Promega). Reactions were incubated at 94°C 705 
for 1 minute followed by 35 cycles at 93°C for 20 seconds, at 64.1°C for 30 seconds and 72°C for 1 706 
minute. The obtained products were resolved by capillary electrophoresis with the eGene HDA-707 
GT12 Multi-Channel Genetic Analyzer (eGene Inc.), quantified, and finally ligated into the 708 
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pCRII-TOPO TA vector (Invitrogen). Ligation mixes were used to transform chemically 709 
competent TOP-10 E. coli cells (Invitrogen), and individual clones (at least 30 clones per 710 
electrophoresed sample) were sequenced by direct Sanger sequencing using BigDye terminator 711 
V1.1 (Applied Biosystems) with insert-specific primers. Sequencing data were analyzed using the 712 
CLC Bio software (Qiagen) and compared with the corresponding human reference sequence 713 
(build hg19).  714 
 715 
Next generation metabolomics analysis - High resolution untargeted metabolomics analysis of 716 
body fluids was performed using UHPLC-Qtof mass spectrometry. Cerebrospinal fluid and 717 
heparinised plasma samples were deproteinised in methanol/ethanol (50:50 v/v; 100 µL sample 718 
plus 400 µL methanol/ethanol). Samples were analysed in duplicate. Two µL sample was applied 719 
to an Acquity HSS T3 reversed phase column (100 x 2.1 mm; 100Å, 1.8 µm) and an Agilent 6540 720 
UHD accurate mass UHPLC Qtof-MS with acquisition in positive and negative mode was used. 721 
Buffers in positive mode consisted of A: 0.1v/v% formic acid/water, B: 0.1 vv% formic acid in 722 
water/methanol (1:99 v/v) was used while in negative mode A: 10 mM acetic acid, B: 10 mM 723 
acetic acid in water/ methanol (1:99 vv). After analysis and XCMS alignment, in house developed 724 
bioinformatics software showed the features (exact m/z, retention time and intensity) deriving 725 
from metabolites that are significantly different in intensity in the patient sample compared to 726 
age- and sex-matched controls. The Human Metabolome Database 3.0 was used to putatively 727 
annotate significantly different features45 This technique, also referred to as “next generation 728 
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metabolic screening”, was clinically validated using body fluids of patients with 25 known inborn 729 
errors of metabolism and introduced in the Nijmegen patient care research setting.  730 
 Proton NMR spectroscopy of body fluids, fibroblast homogenates and model compounds 731 
of N-acetylated sugars was performed on a 500 MHz NMR spectrometer with minor 732 
modifications46. The NMR spectrum of fibroblasts was recorded on a homogenate obtained after 733 
sonification of 7.5 106 cells in D2O. The homogenate was deproteinised over a 10 kD filter and 734 
trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (=TSP) was used as a chemical shift reagent in 735 
the NMR spectrum. The model compounds N-acetylmannosamine, N-acetylgalactosamine, N-736 
acetylglucosamine were purchased from Sigma chemicals and N-acetylmannosamine-6-737 
phosphate from Carbosynth (disodium salt).  738 
 739 
Lectin staining on cultured fibroblasts - Fibroblasts were cultured for 48 h in DMEM 10%FCS 740 
supplemented with 0, 1, and 10 mM ManNAc. After incubation, fibroblasts were trypsinized, 741 
washed twice in Hanks buffered saline solution (HBSS) containing 1% FCS and resuspended at 1 742 
x 10^6 cells/ml. Aliquots of 10^5 cells (100 ul) were incubated with 1mM FITC-labeled 743 
Sambucus nigra lectin (Vector Labs) in HBSS for 20 min on ice, washed twice in HBSS 744 
containing 1% FCS, and analyzed by flow cytometry using a FACScanto II cytometer (BD 745 
Biosciences). 746 
 747 
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ManNAc incorporation in fibroblast culture - Skin fibroblasts were cultured and expanded in 748 
DMEM containing 10% FCS at 37 °C in 5% CO2, and then for 24 hours in the absence of FCS. 749 
For the incorporation experiment, mycoplasma-negative cells were incubated in DMEM, without 750 
serum and antibiotics, with or without 10 mM N-acetylmannosamine (ManNAc), at 37°C in 5% 751 
CO2 for 48 h. After incubation, the medium was removed, cells were harvested in PBS and 752 
collected by low speed centrifugation. The cell pellet was sonicated in 20 mM Tris-HCl, pH 8.0, 5 753 
mM EDTA, 150 mM NaCl, 1 µg aprotinin and 1 mM PMSF and the lysate ultracentrifuged at 754 
30.000 × g for 1 h at 4 °C to pellet the membrane fraction. In the clear supernatant, protein 755 
content was determined with the BCA protein assay (Pierce) and aliquots of the supernatant 756 
were ultrafiltered with Amicon Ultra-0.5 Centrifugal Filter Unit with a cut-off of 3kDa to 757 
separate sialic acid from soluble protein. The dried filtrate was used for sialic acid analysis. The 758 
CMP-sialic acid content was discriminated from free sialic acid by reduction: labelling with the 759 
fluorophore 1,2-diamino-4,5-methylene-dioxybenzene (DMB) requires free keto as well as 760 
carboxyl groups of the sialic acid molecule, and reduction of the keto group prior to the labelling 761 
process precludes the labelling of non-activated sialic acid12. Each lyophilized sample was split in 762 
two aliquots. To reduce free non activated monosaccharides dried samples were dissolved in 0.2 763 
M sodium borate buffer, pH 8.0, containing 0.2 M sodium borohydride, incubated at 0°C o/n 764 
and dried in a SpeedVac concentrator. For fluorescent labelling of sialic acid, samples were 765 
hydrolyzed in 0.2 N trifluoroacetic acid (TFA) for 4 h at 80 °C, dried, redissolved twice in 766 
methanol and dried again. To label sialic acids with DMB, hydrolysates were dissolved in 80 µl of 767 
 41
0.64 mg/ml DMB in 500 mM 2-mercaptoethanol, 9 mM sodium hydrosulfite, 20 mM TFA and 768 
incubated for 2 h at 56 °C. Reactions were then stopped by adding 10 µl of 0.2 M NaOH. The 769 
derivatized sialic acids were then quantified by HPLC on a binary pump system (1525µ Binary 770 
HPLC Pump, Waters) coupled to a fluorescence detector (2475 Multy λ Fluorescence Detector, 771 
Waters) set at λex 372 nm and λem 456 nm. Chromatography was carried out at room 772 
temperature with a LichroCART 250-4 Superspher 100 RP18 (250 × 4 mm) column (Merck) and 773 
LiChrospher 100 RP18 (25 × 4 mm) (Merck) as pre-column. Mobile phases were 774 
methanol/acetonitrile/water/TFA (4:4:92:0.1) and methanol/acetonitrile/water/TFA 775 
(45:45:10:0.1) and the flow rate was 0.3 ml/min12. 776 
 777 
Measurement of the NeuNAc content in fibroblasts – Fibroblasts (~2.5 millon cells) in 250 µl 778 
50 mM Tris/HCl (pH 7.5) were sonicated on ice (3x 8 sec), then centrifuged (10 min, 10.000 g, 4 779 
°C). To 100 µl of the supernatant (lysate) was added 13C3-N-acetyl-neuraminic acid (± 23 µM) as 780 
internal standard and the solution was applied to a 30 kDa filter cup (Amicon Ultra) with 10 µl 781 
2% formic acid in the collection tube for deproteination. After centrifugation for 30 min at 782 
13.000 g and 4 °C, the flow-through was used for quantification of NeuNAc by mass 783 
spectrometry according to published methods47,48. Assays were performed in duplicate and 784 
NeuNAc levels were normalized for protein level in the lysates. 785 
 786 
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Determination on NANS activity in fibroblast cultures – Skin fibroblasts were obtained from 787 
affected individuals and healthy controls and cultured at 37.0°C under 5.0% CO2 in culture 788 
medium E199, supplemented with 10% fetal calf serum and 1% Penicillin/Streptomycin. All 789 
cultures were tested for mycoplasma infection prior to cultivation. We developed an assay for 790 
NANS activity as follows: fibroblasts (~7.5 million cells) in 300 µl 50 mM Tris/HCl pH (7.5) were 791 
sonicated on ice (3x 8 sec), then centrifuged (10 min, 10.000 g, 4 °C). The supernatant (lysate) 792 
was used for protein determination (BCA assay) and for enzyme activity assay. Incubation of N-793 
acetyl-D-mannosamine-6-phosphate disodium salt (Carbosynth, 2 mM) and 20 µl lysate was 794 
done at 37 °C in duplicate in a total reaction volume of 100 µl. The reaction buffer consisted of 50 795 
mM Tris/HCl (pH 7.5), 3 mM phosphoenol-pyruvate (PEP; Roche), and 1 mM MgCl2. Control 796 
incubations without ManNAc-6-P were subtracted as a blanc from the incubations. The 797 
reactions were allowed to proceed for 2.5, 5, and 24 hours and then stopped by freezing (-20 °C). 798 
Samples (100 µl) were deproteinized by addition of 50 µl 13C3-N-acetyl-neuraminic acid (± 23 799 
µM) as internal standard, centrifugation for 30 min at 13.000 g and 4 °C on a 30 kDa filter cup 800 
(Amicon Ultra), and the flow-through was collected in 10 µl 2% formic acid. NeuNAc levels were 801 
quantified by mass spectrometry as described47,48 and normalized for protein level in the lysates. 802 
 803 
Metabolic labeling of sialic acids and glycoproteins in fibroblast cultures  804 
Skin derived fibroblasts were cultured in M199 medium (PAN biotech) supplied with 10% fetal 805 
bovine serum (PAA), non essential amino acids (NEAA) (Gibco), 100 U/mL 806 
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Penicilline/streptomycine (Gibco) and tested for mycoplasma contamination. Eighty percent 807 
confluent cells were further grown for 5 days in medium containing 15 µM of Ac5NeuNAc, 808 
Ac4ManNPoc, or Ac5NeuNPoc. Cells were collected in PBS by scraping and lysed in 150 mM 809 
NaCl, 50 mM TRIS-HCl, pH 7.5, 5 mM EDTA, 0.1% SDS, 1% Triton X-100, and 1× cOmplete® 810 
protease inhibitor cocktail (Roche). To biotinylate propargyloxycarbonyl-containing 811 
glycoproteins, cell lysates were resolved on 10% SDS gels, blotted on polyvinylidene fluoride 812 
(PVDF) membrane and after blocking of unoccupied membrane sites with 5% dry milk in PBS, 813 
incubated with 500 μM CuSO4, 250 μM l-histidine, 100 μM azide-PEG3-biotin, 500 μM sodium 814 
ascorbate in PBS for 1h at 37°C. Biotinylated sialoglycoproteins were visualized by incubation 815 
with Horseradish Peroxidase conjugated Streptavidin (GE Healthcare), followed by signal 816 
development with SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermofisher 817 
Scientific). As a loading control an immunostaining with Anti-GAPDH (Abcam Cat N ab8245) 818 
of the same western blots was used. Based on this protocol, we found that NeuNPoc at 15 µM 819 
concentration would readily label cellular sialoglycans after 5 days of incubation. For ManNPoc 820 
at the same concentration of 15 µM, longer incubation times were required to obtain strong 821 
labeling of glycoconjugates in fibroblasts from healthy donors (Figure 5). 822 
 823 
Determination of glycosylation of plasma proteins - Analysis of plasma transferrin N-824 
glycosylation was done by isoelectric focusing49 as well as by nanochip QTOF mass 825 
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spectrometry50. The mucin-type O-glycosylation of plasma apolipoprotein CIII was done by 826 
isoelectric focusing49.  827 
 828 
Zebrafish studies - Zebrafish were maintained at 28.5 C in a 10/14-h dark/light cycle. Protocols 829 
for experimental procedures were approved by the Research Ethics Board of St. Michaels 830 
Hospital, Toronto, Canada (protocol number ACC660).  To knock down gene expression, we 831 
used splicing blocking morpholino oligonucleotides (MO) for nansa and nansb knockdown plus 832 
a standard control MO (ctrl MO) (for sequences, see Supplementary Table 5). The zebrafish 833 
nansa gene has six exons with the translation start codon in exon 1 (access number 834 
ENSDART0000006708; chr. 1). we designed a splicing blocking morpholino nansa-e3i3 that can 835 
block the splicing donor of exon 3, resulting in intron 3 retention and a truncated protein in 836 
translation (data not shown). Nansb also has 6 exons with translation start codon in exon 1 837 
(access number ENSDART00000169540; chr. 25) and we designed a morpholino nansb-e1i1 to 838 
block the splicing donor site of exon 1 of nansb, resulting in intron 1 retention and a truncated 839 
nansb protein (data not shown). MOs were synthesized by Gene Tools, LLC (for sequences, see 840 
supplementary material) and microinjected individually or in combination into 1 cell stage 841 
zebrafish embryos. We injected individually nansa-e3i3 (4ng/nl) and nansb-e1i1 (4 ng/nl) MOs, 842 
and co-injected nansa-e3i3 (4 ng/nl)/nansb-e1i1 (4 ng/nl) MOs. Each injection was repeated at 843 
least three times. Knock-down of nansa and nansb was confirmed by RT-PCR to confirm 844 
splicing defect and retention of the intron (data not shown). For control MO, embryos were 845 
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injected at 1 cell stage with 4 ng/nl. At least 30 embryos were injected per condition and included 846 
in the analysis.  At 24 hpf, embryos were manually dechorionated. Total RNA was extracted from 847 
embryos at 48 hpf using TRIzol (Invitrogen). The RNA concentration of each sample was 848 
quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). RNA 849 
integrity was verified in 1% agarose gel electrophoresis. The RNA template was converted into 850 
cDNA using Superscript II reverse transcriptase (Invitrogen), and used to amplify a nansa 851 
specific cDNA (for primer sequences, see Supplementary Table 5).  852 
 853 
To visualize the cartilaginous structures, Alcian blue (Sigma) was dissolved in 70% ethanol and 854 
1% hydrochloric acid. The zebrafish embryos (6 dpf) were fixed in 4% paraformaldehyde 855 
overnight at 4 C, and maintained in 100% methanol at -20 0C until processing. The embryos were 856 
washed with phosphate-buffered saline with 0.1% Tween-20 (PBST). The embryos were bleached 857 
in 30% hydrogen peroxide for 2 hours, washed with PBST and transferred into Alcian blue 858 
solution. Embryos were stained overnight at room temperature. The embryos were rinsed 4 times 859 
with acidified ethanol (HCl–EtOH) 5% hydrochloric acid, and 70% ethanol. Embryos were 860 
rinsed for 20 min in HCL-EtOH, and re-hydrated by washing 10 min in a HCL-EtOH/ H2Od 861 
series (75%, 25%, 50%, 50%, 25%, 75%) and 100% H2Od. Embryos were stored in 1 ml of 862 
glycerol-KOH. 863 
 864 
 865 
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